Biopharma R&D Information &
Custom Report Preparation

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.

Prodrug antibodies and cytokines generated by masking technologies provide plenty of opportunities for founders, investors and partnerships

BARCELONA, Spain I October 06, 2021 I La Merie Publishing announced the release of its newest report about antibody and cytokine prodrugs . The report “Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective” provides a landscape description and analysis of prodrug antibodies and […]

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: an emerging new technology

BARCELONA, Spain I July 1, 2021 I La Merie Publishing announced the release of its newest report about in vivo delivery of nucleic acid-encoded antibodies . The report “Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective” provides a landscape […]

Landscape Analysis of Targeted Protein Degradation by Novel PROTACs and Molecular Glues

BARCELONA, Spain I May 14, 2020 I La Merie Publishing announced the release of its newest report about Targeted Protein Degradation. The report “Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective” provides a landscape description and analysis of Targeted […]

How many PD-1 and PD-L1 checkpoint inhibitors do we need?

STUTTGART, Germany I June 19, 2018 I La Merie Publishing released the results of an independent search for and evaluation of PD-1 and PD-L1 immune checkpoint inhibitors in preclinical and clinical development by pharmaceutical companies. This Competitive Intelligence report analyzes the competitive field of PD-1 and PD-L1 Immune Checkpoint Inhibitors as of June 2018 in […]

Druggability of intracellular targets: a challenging, but highly rewarded goal for emerging technologies to generate TCR fusion proteins, TCRL antibodies and cell-permeating biologics

STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are intracellular or secreted targets not accessible for conventional monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy (Uhlen et al., Science, 2015). Thus, the large pool of intracellular protein targets, including overexpressed oncogenic proteins, mutated […]

2016 was another record year of biologics sales with therapeutic antibodies accounting for two-thirds of total biologics sales

STUTTGART, Germany I March 17, 2017 I Sales of branded originator biologics in 2016 continued to reach a record high of US$ 163 bln, a plus of 5.8% compared with the previous year. Growth drivers were therapeutic antibodies fortreatment of cancer and inflammatory diseases, especially the emerging immuno-oncology antibodies and novel anti-inflammatory antibodies different from […]